Navidea biopharmaceuticals announces opening of nine new sites in its pivotal phase 3 trial in rheumatoid arthritis and termination of binding memorandum of understanding with jubilant radiopharma

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the opening of nine additional sites for recruitment into its pivotal nav3-33 phase 3 clinical trial titled “evaluation of tc 99m tilmanocept imaging for the early prediction of anti-tnfΑ therapy response in patients with moderate to severe active rheumatoid arthritis
NAVB Ratings Summary
NAVB Quant Ranking